Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292608 | 0.84 | USP2 (0.52) | USP2SMN1; SMN2NR1H2GPR119ESR2 | |
| SCHEMBL17629419 | 0.81 | USP2 (0.46) | USP2SMN1; SMN2NR1H2GPR119ESR2 | |
| SCHEMBL25770784 | 0.80 | KDM4E (0.44) | NR1H2GPR119MAPK1NAMPTRORC | |
| SCHEMBL17611204 | 0.78 | USP2 (0.46) | USP2SMN1; SMN2NR1H2ESR2MAPK1 | |
| SCHEMBL14043923 | 0.78 | USP2 (0.46) | USP2SMN1; SMN2NR1H2GPR119ESR2 | |
| SCHEMBL3402775 | 0.77 | ELANE (0.35) | USP2SMN1; SMN2NR1H2ESR2NAMPT | |
| SCHEMBL18668387 | 0.76 | USP2 (0.44) | USP2SMN1; SMN2NR1H2ESR2MAPK1 | |
| SCHEMBL25770783 | 0.75 | USP2 (0.43) | USP2SMN1; SMN2NR1H2GPR119ESR2 | |
| SCHEMBL18669485 | 0.73 | HSD17B10 (0.43) | USP2SMN1; SMN2NR1H2GPR119NAMPT | |
| SCHEMBL1394242 | 0.73 | USP2 (0.44) | USP2SMN1; SMN2NR1H2GPR119ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, FASN | USP2 4542/4885SMN1; SMN2 2174/4885NR1H2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.